[en] The value of serum neopterin as tumor marker was verified in 104 breast cancer patients. Based on the results the evaluation of neopterin cannot be recommended, neither for the decision of treatment after primary therapy nor for monitoring of the breast cancer. (author)
Original Title
Untersuchungen zur Relevanz des Tumormarkers Neopterin fuer die Therapieentscheidung und Verlaufskontrolle bei Mammakarzinom